ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1404	National Cancer Institute	Html	en	Sleep Disorders (PDQ®)–Patient Version	Expert-reviewed information summary about causes and management of sleep disorders in people with cancer.	normal sleep patterns 0.734479 Relaxation therapy 0.493159 moderate sleep disorders 0.656166 sleeping problems 0.484122 PDQ cancer information 0.646663 sleep medicines 0.601935 health care team 0.479673 clinical trials 0.518721 sleep history 0.612308 sleep apnea 0.593611 cancer patient sleeps 0.499804 cancer information summary 0.579061 clinical trial 0.483994 breast cancer prevention 0.483786 good sleep habits 0.703452 cancer patients 0.541537 treatment instructions 0.483188 sleep problems 0.627478 mild sleep disorders 0.656367 NCI’s PDQ 0.480637 NCI PDQ cancer 0.525102 Common cancer treatments 0.495476 sleep disorder clinic 0.627008 deep sleep 0.635758	treatment 0.54776 cancer prevention 0.48441 lighter sleep 0.598128 Cancer Information Service 0.493437 REM sleep 0.662129 sleep 0.949433 good night 0.507447 National Cancer Institute 0.585654 sleep repeat 0.634943 light sleep 0.635787 Palliative Care Editorial 0.524141 new treatment 0.481731 sleep disorders 0.849206 sleep restriction 0.605553 Cancer Care page 0.486706 Care Editorial Board 0.525467 health 0.498616 PDQ summary 0.533115 sleep disorder 0.712776 sleep problem 0.601447 cancer information summaries 0.498019 comprehensive cancer information 0.497854 cancer 0.67715 stimulus control 0.540953	CLICK HERE
1463	National Cancer Institute	Html	en	Renal Cell Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of renal cell cancer.	2-week washout period 0.566416 Transitional Cell Cancer 0.481465 treatment 0.601534 Patient Preference Study 0.474292 sunitinib treatment 0.529856 10-week treatment period 0.482517 VEGF receptors 0.467264 well-differentiated renal adenocarcinomas 0.509726 pazopanib arm 0.470964 sunitinib side effects 0.517044 true treatment break 0.474342 primary endpoint 0.499973 patients preferred pazopanib 0.531227 immediately surrounding tissue 0.462945 6-week treatment cycle 0.515867 trial 0.472067 Late tumor recurrence 0.47026 Pazopanib Versus Sunitinib 0.55357 cytoreductive nephrectomy extends 0.466923 High-dose IL-2 0.463042 patient treatment 0.463771 occasional selected patients 0.50375 overall survival 0.481487 rating scale 0.463587	toxic effects 0.499682 axitinib versus sorafenib 0.467683 sorafenib patients 0.470445 sunitinib 0.625595 renal cell cancer 0.570239 recurrent renal cell 0.504482 metastatic disease 0.476849 external-beam radiation therapy 0.463579 patients 0.74513 Metastatic Kidney Cancer 0.465785 initial cytoreductive nephrectomy 0.466065 median PFS time 0.4636 renal adenomas 0.481736 4-week treatment cycle 0.477666 renal cell carcinoma 0.969838 renal cell carcinoma. 0.553709 transitional cell carcinomas 0.485832 clear-cell renal cell 0.607225 renal cell cancers 0.532142 renal pelvis 0.520062 10-week treatment periods 0.476333 metastatic renal cell 0.598995 renal cell carcinomas 0.527788	CLICK HERE
1524	National Cancer Institute	Html	en	Endometrial Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of endometrial cancer.	cancer treatment 0.541916 Lymph node dissection 0.478324 metastatic endometrial cancer 0.510561 body 0.511838 PDQ cancer information 0.531329 clinical trial search 0.465384 uterus 0.585793 endometrial cancer spreads 0.509404 mTOR inhibitors 0.464666 clinical trials 0.736061 cancer information summary 0.508345 clinical trial 0.5843 Low-risk endometrial cancer 0.501844 breast cancer patients 0.483969 patients 0.494506 NCI PDQ cancer 0.479485 malignant tumor cells 0.467809 lymph nodes 0.52827 endometrial hyperplasia 0.468477 radiation therapy 0.605187 Treatment Editorial Board 0.469208 endometrial cancer 0.889926 radical hysterectomy 0.471844 treatment 0.622425 cancer prevention 0.463817	new cancer treatments 0.470535 NCI-supported cancer 0.463476 cancer cells 0.753566 Cancer Information Service 0.471559 specific cancer cells 0.479989 treatment clinical trials 0.48357 High-risk endometrial cancer 0.500552 endometrial tissue 0.464689 National Cancer Institute 0.508844 new treatment 0.504217 cervix 0.474629 external radiation therapy 0.482834 non-polyposis colon cancer 0.477796 tissue samples 0.463584 cancer research process 0.465542 cancer clinical trials 0.501833 stage 0.522219 Endometrial Cancer Treatment 0.516218 Recurrent endometrial cancer 0.629078 fallopian tubes 0.494755 cancer information summaries 0.469865 treatment options 0.466033 comprehensive cancer information 0.469896 internal radiation therapy 0.504839	CLICK HERE
1740	National Cancer Institute	Html	en	Hair Dyes and Cancer Risk	A fact sheet that reviews research about the possibility of a connection between personal hair dye use and cancer.	female breast cancer 0.364162 hair dye 0.94208 hair dye products 0.547022 hair dyes 0.824788 Kupelnick B. Personal 0.356107 Modern hair dyes 0.445893 C. Personal hair 0.381701 case-control study 0.408793 bladder cancer 0.729938 consumer exposure study 0.34979 permanent hair dye 0.484417 increased risk 0.395633 case-control studies 0.347772 bladder cancer risk 0.47239 Montes-Martinez A. Personal 0.354703 IARC Working Group 0.350056 permanent hair dyes 0.502056 MR. Bladder cancer 0.389163 American Journal 0.365295 temporary hair dyes 0.442658 hair coloring products 0.388447 currently marketed products 0.354822 leukemia/small lymphocytic lymphoma 0.349931 colorless dye 0.417079 A. Bladder cancer 0.391043	Cancer Epidemiology Biomarkers 0.364493 International Journal 0.379963 public health impact 0.349406 black permanent dyes 0.401612 color dyes 0.375257 Personal permanent hair 0.383955 United States 0.383182 adult acute leukemia 0.391088 non-Hodgkin lymphoma 0.350907 conflicting results 0.412706 bladder cancer study 0.39321 earlier hair dyes 0.42871 personal hair dye 0.756765 studies 0.389653 bladder-cancer risk 0.359564 public health 0.351318 dark-colored dyes 0.399225 follicular lymphoma 0.348182 recent dye formulations 0.42394 aromatic amines 0.360034 hair dye formulations 0.474224 specific NHL subtypes 0.351636 hair dye users 0.497516 et al 0.482744	CLICK HERE
1876	National Cancer Institute	Html	es	Tratamiento de los tumores de ovario de bajo potencial maligno (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de ovario de bajo potencial maligno.	estadio lV 0.336073 Obstet Gynecol 0.332535 Are borderline tumors 0.338893 Radium Hospital from 0.383601 low malignant 0.947577 Norwegian Radium Hospital 0.384329 Abeler VM 0.345874 long-term follow-up 0.429878 serous tumors 0.367951 Leake JF 0.387334 ovary treated 0.34981 Instituto Nacional 0.327748 malignant potential with 0.326796 Rosenshein NB 0.34897 Federation Internationale 0.32197 University Medical Center 0.328522 Kaern J 0.406737 endometrioid tumors 0.337973 Gynecologic Oncology Group 0.336842 Gynecol Oncol 0.811816 lavados peritoneales 0.350751 New York University 0.326742 Icb Tumor 0.324006 retrospective study 0.363127 cellular dna content 0.335807	Bell DA 0.339598 patients with borderline 0.366646 malignant potential treated 0.323909 borderline tumors with 0.347412 borderline tumors 0.629125 clinicopathologic features 0.350407 tumores aneuploides 0.321014 estadio ia 0.33807 Oncology Group study 0.347633 with borderline tumors 0.383311 IIIa Tumor 0.323737 Kurman RJ 0.323851 PDQ Tratamiento 0.323544 Gynecol Pathol 0.337197 New York 0.330732 York University Medical 0.327419 Currie JL 0.350075 Ovarian epithelial tumors 0.334479 Clin Oncol 0.355682 Tropé CG 0.345953 Lage JM 0.321478 tumor residual macroscópico 0.331365 Gynecol Cancer 0.321099 serous borderline tumors 0.4289	CLICK HERE
1931	National Cancer Institute	Html	es	Tratamiento de los tumores de ovario de bajo potencial maligno (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de los tumores de ovario de bajo potencial maligno.	potencial maligno recidivantes 0.922565 siguientes procedimientos 0.427427 tarde.ampliar ecografía abdominal 0.259992 estadio iv 0.702134 estadio tardío quizás 0.295045 siguientes aspectos 0.213133 rayos x 0.188575 estadio ic 0.522053 estadio ib 0.526427 estadio ia 0.52265 National Cancer Institute 0.172435 siguientes riesgos 0.159887 tratamiento quizás 0.234452 Instituto Nacional 0.353292 áreas anormales.ampliar examen 0.232843	estadio iiia 0.49525 PDQ Tratamiento 0.250127 estadio iiic 0.497145 estadio iiib 0.498374 estadio iia 0.510853 estadio iib 0.521745 estadio iic 0.517926 Physician Data Query 0.359777 potencial maligno causa 0.737758 maligno causa efectos 0.613505 siguientes enlaces 0.168488 ecografía transvaginal.Ampliar 0.196606 histerectomía abdominal 0.202556 siguientes pruebas 0.233116	CLICK HERE
1996	National Cancer Institute	Html	es	Comunicación en la atención del cáncer (PDQ®)–Versión para pacientes	Resumen de la información revisada por expertos acerca de la comunicación con el paciente de cáncer y sus familiares, que incluye los aspectos distintivos de la comunicación con pacientes de cáncer, los factores que afectan la comunicación y la capacitación en aptitudes para la comunicación.	comunicación mejora 0.843776 familia ayuda 0.776248 siguientes casos 0.791497 Physician Data Query 0.942554 mejores decisiones 0.835028 siguientes preguntas 0.768644 suministra información 0.764377 salud ayuda 0.830465 médico ayuda 0.964949	National Cancer Institute 0.757167 siguientes indicaciones 0.779865 ¿Cuáles archivos 0.761738 siguientes riesgos 0.741613 PDQ Comunicación 0.825783 comunicación ayuda 0.895884 Instituto Nacional 0.809598 ¿Cuáles problemas 0.755893	CLICK HERE
2106	National Cancer Institute	Html	es	Exámenes de detección del cáncer de endometrio (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de endometrio.	PDQ Tratamiento 0.669269 general causa síntomas 0.588555 Visuals Online 0.525614 PDQ Exámenes 0.596864 cáncer.Los exámenes 0.641713 Physician Data Query 0.681868 pequeña cantidad 0.54391 Estados Unidos 0.562116 cuello uterino 0.811632	prevención revisa 0.531482 ecografía endovaginal 0.56717 información ayuda 0.538498 National Cancer Institute 0.545187 ecografía transvaginal 0.942856 siguientes riesgos 0.532576 siguientes sumarios 0.618993 Instituto Nacional 0.58569	CLICK HERE
15641	National Cancer Institute	Html	en	Research Performance Progress Report (RPPR)	Find more information about the RPPR, which documents recipient accomplishments and compliance with terms of award.	non-competing renewal 0.483928 public access policy 0.676757 NCI program 0.46997 business official 0.461707 grants management specialist 0.511753 Institutional Review Board 0.501375 recipient accomplishments 0.470927 progress reports 0.710572 budget period 0.703772 Performance Progress Report 0.705145 competing project period 0.527715 NCBI 0.472549 NIH staff 0.493692 Type 4s 0.462417 additional information 0.516454 email notification reminders 0.504215 award progress reports 0.597891 PubMed Central ID 0.510154 budget periods 0.468611 Progress Report Additional 0.614182 multiple PIs 0.466396 contact PI 0.464615 award process 0.523874 Management staff review 0.506533 final peer-reviewed journal 0.498525	grants management staff 0.612225 additional information online 0.514579 recipient wishes 0.463817 different schedule 0.465588 Institutional Animal Care 0.498988 annual progress reports 0.586399 progress report 0.93768 scientific progress 0.590143 subsequent budget period 0.638937 final progress report 0.600792 NIH applications 0.499628 eRA Commons 0.829812 full-text papers 0.492864 Non-competing continuation 0.468466 NCI staff 0.465398 Streamlined Noncompeting Award 0.520709 NIH funds 0.496167 NIH Public Access 0.629563 RPPR 0.513098 NIH funding 0.492377 Research Performance Progress 0.694309 Business Technology Transfer 0.507309 incomplete applications 0.461976 Small Business 0.499434	CLICK HERE
16826	National Cancer Institute	Html	en	Early Onset Malignancies Initiative	The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations.	community sites 0.48513 control group 0.496806 certain minority populations 0.77365 exome sequencing 0.513318 ethnic populations 0.59564 ethnic groups 0.477288 multiple platforms 0.483426 early detection 0.483135 tumor behavior 0.507221 cutting-edge genomic characterization 0.794697 early age 0.515521 genomic datasets 0.554094 patient populations 0.708455 multiple myeloma 0.479782 critical research 0.469762 rich genomic data 0.741156 cancer types 0.666255 Thorough clinical data 0.657553 extensive data 0.513023 clinical measures 0.479008 molecular targets 0.47719 TCGA 0.415616 tumor progression 0.525349 earlier age 0.508182	higher rates 0.504515 important insights 0.491579 molecular drivers 0.46961 cancer type 0.492461 NCI Genome Characterization 0.808398 early disease 0.497354 clinical updates 0.489197 disease monitoring 0.476658 Genome Characterization Pipeline 0.932301 collaborative initiative 0.505734 NCI genomic characterization 0.824673 EOMI 0.680345 NCI Community Oncology 0.754977 total RNA sequencing 0.668278 underrepresented minorities 0.53639 Cancer Genome Atlas 0.669216 tissue samples 0.659999 Early Onset Malignancies 0.747146 EOMI data 0.528397 treatment response 0.492799 cancer risk 0.496991 genome sequencing 0.549082 Cancer Prevention 0.5334 normal tissue samples 0.654735	CLICK HERE